Pure Global

IVD Department qualitative test for specific IgM antibodies against HSV-1 and/or HSV-2 - Vietnam Registration 2400638ĐKLH/BYT-HTTB

Access comprehensive regulatory information for IVD Department qualitative test for specific IgM antibodies against HSV-1 and/or HSV-2 in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2400638ĐKLH/BYT-HTTB. The authorized representative in Vietnam is CÔNG TY TNHH THIẾT BỊ NHẬT ANH.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
2400638ĐKLH/BYT-HTTB
Registration Details
Vietnam MOH Registration: 2400638ĐKLH/BYT-HTTB
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

IVD Department qualitative test for specific IgM antibodies against HSV-1 and/or HSV-2
VN: Bộ IVD xét nghiệm định tính kháng thể IgM đặc hiệu với HSV-1 và/hoặc HSV-2
Risk Class TTBYT Loại C

Registration Details

2400638ĐKLH/BYT-HTTB

18006167/ĐKLH-BYT-TB-CT

Theo theo phụ lục

Theo phụ lục

Company Information

Technical Details

1. LIAISON HSV-1/2 IgM: The LIAISON HSV-1/2 IgM test uses the CLIA (Chemiluminescent Immunoassay) technology to qualitatively detect the specific IgM antibodies against Herpes simplex virus type 1 and/or type 2 (HSV-1 and/or HSV-2) in human serum or plasma samples. The test is performed on the LIAISON automated immunoassay analyzer. 2. LIAISON Control HSV-1/2 IgM: The LIAISON Control HSV-1/2 IgM (negative and positive) materials are used in the CLIA (Chemiluminescent Immunoassay) to assess the reliability of the test runs. The performance characteristics of the LIAISON Control HSV-1/2 IgM materials are not established for any other test or system other than the LIAISON, LIAISON XL and LIAISON XS immunoassay analyzers.

Dates and Status

May 10, 2024